UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a SMN2 splicing modifier

British journal of clinical pharmacology, 2019-01, Vol.85 (1), p.181-193

2019

Volltextzugriff (PDF)

Addressing Today's Absorption, Distribution, Metabolism, and Excretion (ADME) Challenges in the Translation of In Vitro ADME Characteristics to Humans: A Case Study of the SMN2 mRNA Splicing Modifier Risdiplam

Drug metabolism and disposition, 2022-01, Vol.50 (1), p.65-75

2022

Volltextzugriff (PDF)

Discovery of Risdiplam, a Selective Survival of Motor Neuron‑2 (SMN2) Gene Splicing Modifier for the Treatment of Spinal Muscular Atrophy (SMA)

Journal of medicinal chemistry, 2018-08, Vol.61 (15), p.6501-6517

2018

Volltextzugriff (PDF)

Risdiplam distributes and increases SMN protein in both the central nervous system and peripheral organs

Pharmacology research & perspectives, 2018-12, Vol.6 (6), p.e00447-n/a

2018

Volltextzugriff (PDF)

Calibration of in vitro multidrug resistance protein 1 substrate and inhibition assays as a basis to support the prediction of clinically relevant interactions in vivo

Drug metabolism and disposition, 2014-09, Vol.42 (9), p.1411-1422

2014

Volltextzugriff (PDF)

Mechanistic Modeling of Hepatic Transport from Cells to Whole Body: Application to Napsagatran and Fexofenadine

Molecular pharmaceutics, 2009-12, Vol.6 (6), p.1716-1733

2009

Volltextzugriff (PDF)

The need for human breast cancer resistance protein substrate and inhibition evaluation in drug discovery and development: why, when, and how?

Drug metabolism and disposition, 2014-09, Vol.42 (9), p.1466-1477

2014

Volltextzugriff (PDF)

Response to "Breast cancer resistance protein substrate and inhibition evaluation: why, when, and how?"

Drug metabolism and disposition, 2014-12, Vol.42 (12), p.1981-1981

2014

Volltextzugriff (PDF)

Prediction of pharmacokinetic profile of valsartan in human based on in vitro uptake transport data

Journal of pharmacokinetics and pharmacodynamics, 2009-12, Vol.36 (6), p.585-611

2009

Volltextzugriff (PDF)

PK/PD assessment in CNS drug discovery: Prediction of CSF concentration in rodents for P-glycoprotein substrates and application to in vivo potency estimation

Biochemical pharmacology, 2013-06, Vol.85 (11), p.1684-1699

2013

Volltextzugriff (PDF)

Characterization of the Transmembrane Transport and Absolute Bioavailability of the HCV Protease Inhibitor Danoprevir

Clinical pharmacokinetics, 2015-05, Vol.54 (5), p.537-549

2015

Volltextzugriff (PDF)

Design, data analysis, and simulation of in vitro drug transport kinetic experiments using a mechanistic in vitro model

Drug metabolism and disposition, 2008-12, Vol.36 (12), p.2434-2444

2008

Volltextzugriff (PDF)

Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies

Drug metabolism and disposition, 2012-08, Vol.40 (8), p.1556-1565

2012

Volltextzugriff (PDF)

Prediction of Pharmacokinetic Profile of Valsartan in Humans Based on in vitro Uptake-Transport Data

Chemistry & biodiversity, 2009-11, Vol.6 (11), p.1975-1987

2009

Volltextzugriff (PDF)

Relationship Between Central and Peripheral SMN Protein Increase Upon Treatment with RO7034067 (RG7916) (S46.007)

Neurology, 2018-04, Vol.90 (15_supplement)

2018

Volltextzugriff (PDF)

Specific Correction of Alternative Survival Motor Neuron 2 Splicing by Small Molecules: Discovery of a Potential Novel Medicine To Treat Spinal Muscular Atrophy

Journal of medicinal chemistry, 2016-07, Vol.59 (13), p.6086-6100

2016

Volltextzugriff (PDF)

Effects of Cytochrome P450 3A4 Inhibitors—Ketoconazole and Erythromycin—on Bitopertin Pharmacokinetics and Comparison with Physiologically Based Modelling Predictions

Clinical pharmacokinetics, 2016-02, Vol.55 (2), p.237-247

2016

Volltextzugriff (PDF)

New strategies to address drug-drug interactions involving OATPs

Current opinion in drug discovery & development, 2007-01, Vol.10 (1), p.74

2007

Volltextzugriff (PDF)

In vitro profiling of the metabolism and drug-drug interaction of tofogliflozin, a potent and highly specific sodium-glucose co-transporter 2 inhibitor, using human liver microsomes, human hepatocytes, and recombinant human CYP

Xenobiotica, 2015-03, Vol.45 (3), p.230-238

2015

Volltextzugriff (PDF)

Happy birthday Brigitte

The Guardian (London), 2009-09, p.6-9

Poirier, Agnès

2009

Volltextzugriff (PDF)

Oral SMN2 splicing modifiers in spinal muscular atrophy: Proof-of-mechanism and ongoing clinical studies

European journal of paediatric neurology, 2017-06, Vol.21, p.e226-e226

2017

Volltextzugriff (PDF)

Until now, Strauss-Kahn's libido wasn't a problem for the French

New statesman (1996), 2011-05, Vol.140 (5054), p.23

Poirier, Agnes

2011

Volltextzugriff (PDF)

Entente cordiale

New Statesman, 2009, Vol.138 (4956), p.51

Poirier, Agnes

2009

Volltextzugriff (PDF)

The Pope's plot against secularism

New statesman (1996), 2008-09, Vol.137 (4915), p.28

Poirier, Agnes

2008

Volltextzugriff (PDF)

1 – 25 von 123

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(60)
Mit Volltextzugriff
(106)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

New Statesman
(16)
New York Times
(7)
Drug Metabolism And Disposition
(6)
The Guardian
(5)
The Spectator
(5)
Plos Genetics
(4)
The New York Times
(4)
Times
(4)
British Journal Of Clinical Pharmacology
(3)
Spectator
(3)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

A phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a SMN2 splicing modifier

Addressing Today's Absorption, Distribution, Metabolism, and Excretion (ADME) Challenges in the Translation of In Vitro ADME Characteristics to Humans: A Case Study of the SMN2 mRNA Splicing Modifier Risdiplam

Discovery of Risdiplam, a Selective Survival of Motor Neuron‑2 (SMN2) Gene Splicing Modifier for the Treatment of Spinal Muscular Atrophy (SMA)

Risdiplam distributes and increases SMN protein in both the central nervous system and peripheral organs

Calibration of in vitro multidrug resistance protein 1 substrate and inhibition assays as a basis to support the prediction of clinically relevant interactions in vivo

Mechanistic Modeling of Hepatic Transport from Cells to Whole Body: Application to Napsagatran and Fexofenadine

The need for human breast cancer resistance protein substrate and inhibition evaluation in drug discovery and development: why, when, and how?

Response to "Breast cancer resistance protein substrate and inhibition evaluation: why, when, and how?"

Prediction of pharmacokinetic profile of valsartan in human based on in vitro uptake transport data

PK/PD assessment in CNS drug discovery: Prediction of CSF concentration in rodents for P-glycoprotein substrates and application to in vivo potency estimation

Characterization of the Transmembrane Transport and Absolute Bioavailability of the HCV Protease Inhibitor Danoprevir

Design, data analysis, and simulation of in vitro drug transport kinetic experiments using a mechanistic in vitro model

Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies

RG7774 (Vicasinabin), an orally bioavailable cannabinoid receptor 2 (CB2R) agonist, decreases retinal vascular permeability, leukocyte adhesion, and ocular inflammation in animal models

Prediction of Pharmacokinetic Profile of Valsartan in Humans Based on in vitro Uptake-Transport Data

Relationship Between Central and Peripheral SMN Protein Increase Upon Treatment with RO7034067 (RG7916) (S46.007)

Specific Correction of Alternative Survival Motor Neuron 2 Splicing by Small Molecules: Discovery of a Potential Novel Medicine To Treat Spinal Muscular Atrophy

Effects of Cytochrome P450 3A4 Inhibitors—Ketoconazole and Erythromycin—on Bitopertin Pharmacokinetics and Comparison with Physiologically Based Modelling Predictions

New strategies to address drug-drug interactions involving OATPs

In vitro profiling of the metabolism and drug-drug interaction of tofogliflozin, a potent and highly specific sodium-glucose co-transporter 2 inhibitor, using human liver microsomes, human hepatocytes, and recombinant human CYP

Happy birthday Brigitte

Oral SMN2 splicing modifiers in spinal muscular atrophy: Proof-of-mechanism and ongoing clinical studies

Until now, Strauss-Kahn's libido wasn't a problem for the French

Entente cordiale

The Pope's plot against secularism

Suchergebnisse filtern